Overview
BMY market data
Price History
BMY price chart
Valuation & Profitability
- P/E (TTM)
- 21.30 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $3.46 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 409.7% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $42.52 – $62.89 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $127.3K · P/B 5.94 · P/S 2.63.
Company news
Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsightGlobenewswire Inc · Jul 23, 2026, 5:15 PM
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
Prediction: U.S. Value Stocks Will Outperform for 10 Years. Which ETFs Should You Buy?The Motley Fool · Jul 21, 2026, 7:31 PM
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsightGlobenewswire Inc · Jul 21, 2026, 6:30 PM
BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen FortschrittGlobenewswire Inc · Jul 21, 2026, 11:15 AM
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026Globenewswire Inc · Jul 21, 2026, 11:15 AM
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AIBenzinga · Jul 20, 2026, 2:05 PM
Bristol Myers Squibb To Expand Compute Infrastructure To Deploy NVIDIA DGX SuperPOD With DGX Vera Rubin NVL72 SystemsBenzinga · Jul 20, 2026, 11:02 AM
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS InsiderGlobenewswire Inc · Jul 15, 2026, 3:15 PM